Site search
2887 results for '' found
A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN P
A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN P
/
A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTA
A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTA
/
An open-label, non-randomized, single-arm pilot study to evaluate the safety and efficacy of multiple pulsed focused ultrasound treatment in patients with drug resistant temporal lobe epilepsy (N
An open-label, non-randomized, single-arm pilot study to evaluate the safety and efficacy of multiple pulsed focused ultrasound treatment in patients with drug resistant temporal lobe epilepsy (N
/
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies (NCT04824794)
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies (NCT04824794)
/
An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of Cevostamab (BFCR4350A) in patients with relapsed or refractory multiple myeloma (NCT032
An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of Cevostamab (BFCR4350A) in patients with relapsed or refractory multiple myeloma (NCT032
/
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome (NCT04623541)
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome (NCT04623541)
/
A Phase I/II, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chr
A Phase I/II, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chr
/
An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants with Parkinson’s Disease With or Without a Pathogenic GBA1 Mutation (NCT
An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants with Parkinson’s Disease With or Without a Pathogenic GBA1 Mutation (NCT
/
FRONTIER-AP: Randomized controlled trial of endovascular versus standard medical therapy for stroke with medium sized vessel occlusion (ACTRN12621001746820)
FRONTIER-AP: Randomized controlled trial of endovascular versus standard medical therapy for stroke with medium sized vessel occlusion (ACTRN12621001746820)
/
Frailty response in patients with aortic stenosis undergoing transcatheter aortic valve implantation; a cluster randomised controlled trial (ACTRN12624000318583)
Frailty response in patients with aortic stenosis undergoing transcatheter aortic valve implantation; a cluster randomised controlled trial (ACTRN12624000318583)
/